Explore Vaccination Progress by U.S. State
With dozens of COVID-19 vaccines now in clinical trials, it is important to understand the accelerated timelines for development, the different types of vaccines available, and the facts related to vaccine safety and efficacy. Additionally, as vaccines are approved, we will track data on vaccination efforts.
Explore how U.S. states delivered their supplies of COVID-19 vaccines to their residents at vastly different speeds that led to vastly different results.
An interactive tool from our vaccine experts that explores how a vaccine is developed and the differences between a typical timeline and an accelerated timeline.
VIEW-hub is a publicly available interactive tool that displays up-to-date information on vaccine characteristics, and vaccine introduction and use globally. Vaccines include COVID-19 as well as many childhood vaccines in routine immunization programs.
COMIT, the COVID-19 Maternal Immunization Tracker, provides a global picture of national public health policies that influence access to COVID-19 vaccines for pregnant and lactating people.
The Johns Hopkins International Vaccine Access Center provides free, online training to equip people with knowledge to debunk false claims about vaccinations.
Emergency use authorization for Pfizer/BioNTech’s vaccine for U.S. children is unlikely to lead to widespread vaccinations among the nation’s 28 million 5-to-11-year-olds.
Nearly 60% of the U.S. population is fully vaccinated. All of Africa: just 6%. Yet the United States is expanding boosters and authorizing vaccines for children age 5 to 11 years old – and hoarding and wasting additional doses.
This series of brief reports will shed light on COVID-19 vaccine development, allocation and deployment in the United States and globally. Topics will include ensuring the safety and efficacy of Covid-19 vaccines, principles for vaccine allocation, strategies for deployment and delivery of Covid-19 vaccines, vaccine confidence and demand, and the economics of Covid-19 vaccines.
COVID-19 VACCINE MATTERS: A blog series discussing the evolving science and policy of COVID-19 vaccines, led by internationally renowned experts in vaccine development, Dr. Larry Corey of the Univeristy of Washington, and Dr. Chris Beyrer of Johns Hopkins University.
Johns Hopkins University and the University of Washington hosted a high-level symposium, “The Scientific Integrity of COVID-19 Vaccine Efficacy Trials: From Clinical Trials to Public Allocation,” that explored complex issues, brought together leading voices in the field, and put forward a concise plan for protecting the scientific integrity of these ongoing efforts.
According to the Centers for Disease Control and Prevention (CDC), about 38.7% of fully vaccinated Americans have now gotten either their COVID-19 booster or third vaccine dose.
Having been triple-vaccinated, plus granted some immunity from my recent bout of COVID, am I now protected against another infection?
An Omicron-specific COVID vaccine will be ready by March but some experts warn it could be “too late” due to the variant’s highly transmissible nature.
Follow-up data from clinical trials demonstrate that the Pfizer-BioNTech COVID-19 vaccine is 100% effective in 12- to 15-year-olds even after four months.
More people in the United States have died from COVID-19 this year than died last year, before vaccines were available.
More states announced that they will administer boosters to any fully vaccinated adults who want them, as long as it has been six months since their second doses of either the Pfizer-BioNTech or the Moderna vaccines or two months since their first Johnson & Johnson shots.
The White House laid out plans Wednesday for children between the ages of 5 and 11 to soon receive the COVID-19 vaccine.
The debate over whether Americans should receive a booster dose of the Pfizer/BioNTech COVID-19 vaccine moved to a panel of independent expert advisers to the U.S. Food and Drug Administration.
Johns Hopkins Center for Health Security Senior Scholar Jennifer Nuzzo discusses the potential for COVID-19 vaccine boosters to be approved by the U.S. Food and Drug Administration.
Many experts are questioning whether there is enough evidence proving a need for boosters given that the vaccines remain effective at what they were intended to do—preventing serious disease, hospitalization, and death from COVID-19.